Advertisement

Topics

With New Data, Amgen Tries Again for FDA OK of Osteoporosis Drug

11:51 EDT 13 Jul 2018 | Xconomy

More than a year after the FDA rejected Amgen’s experimental osteoporosis drug due to safety concerns, the Thousand Oaks, CA, company has teed up a new application. The Amgen (NASDAQ: AMGN) drug, romosozumab (Evenity), is an antibody treatment meant to strengthen bones and reduce the chance that they could break. But while romosozumab did lower […]

Original Article: With New Data, Amgen Tries Again for FDA OK of Osteoporosis Drug

NEXT ARTICLE

More From BioPortfolio on "With New Data, Amgen Tries Again for FDA OK of Osteoporosis Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...